Abstract
SummaryBackgroundConsensus guidelines advocate general skincare for rosacea patients.ObjectivesTwo independent studies were performed to assess whether a tinted daily SPF‐30 facial moisturizer (DFM30) improves barrier function of dry skin and the efficacy and tolerability of DFM30 on rosacea‐prone skin.MethodsIn study 1, electrical capacitance (EC) and transepidermal water loss (TEWL) were measured at baseline, 2, 4, 8, and 24 hours after a single application of DFM30 and on a control site in 21 healthy females with dry skin. Study 2 evaluated 33 females with mild to moderate rosacea and nontransient erythema. Efficacy and tolerability after once‐daily DFM30 were assessed using a chromameter, image analysis of photographs, and trained rater and patient evaluations up to day 22.ResultsIn study 1, EC showed statistically significant increases at 2, 4, and 8 hours, and TEWL showed statistically significant decreases 2, 4, 8, and 24 hours after DFM30 application to healthy females compared to baseline. In study 2, covering skin redness improved significantly after DFM30 application on day 1; 33.3% showed improved covering skin redness compared to baseline. Patients reported significantly less redness on day 8 than day 3. Feelings of dryness and tightness/tension were lower 30 minutes after first application. Feeling of dryness was lower than baseline after 3 days, 1 and 3 weeks. Image analysis suggested redness was significantly lower on day 22 compared to baseline. Chromameter readings showed significantly lower erythema on the cheek compared to baseline. All patients stated that DFM30 relieves and neutralizes visible redness who also indicated that they would purchase DFM30, and the product was well tolerated.ConclusionsThese studies show that DFM30 is suitable as part of the skincare regimens advocated by ROSacea COnsensus (ROSCO) for rosacea patients. DFM30 is an effective moisturizer that improves cutaneous barrier function and the appearance of rosacea‐prone skin.
Highlights
5%‐10% of the population suffers from rosacea, a chronic inflammatory skin disorder.[1,2] The chronic inflammation that underlies rosacea can result in a variety of signs and symptoms that include flushing, telangiectasia, inflammatory lesions, and ocular manifestations.[3]
The two studies presented in this paper show that the DFM30 is suitable as part of the skincare regimens advocated by ROSacea COnsensus (ROSCO) for rosacea patients, enhances cutaneous barrier function, and improves the visible appearance of rosacea‐prone skin
The two studies in this paper show that DFM30 is suitable as part of the skincare regimens advocated by ROSCO for patients with rosacea
Summary
5%‐10% of the population suffers from rosacea, a chronic inflammatory skin disorder.[1,2] The chronic inflammation that underlies rosacea can result in a variety of signs and symptoms that include flushing, telangiectasia, inflammatory lesions, and ocular manifestations.[3] Two features, seem to be diagnostic of rosacea: firstly, persistent erythema that affects the central face and that shows periodic intensification and, secondly, phyma, especially affecting the nose.[3] As rosacea affects facial appearance, the condi‐ tion can have a marked psychological impact and undermine health‐ related quality of life.[4,5,6,7] Against this background, the global ROSacea COnsensus (ROSCO) panel recommended tailoring treatment according to the phenotype (eg transient and persistent erythema, inflammatory papules and pustules, telangiectasia and phyma). All ro‐ sacea patients should be educated on good general skincare, which is the main strategy to manage secondary features, such as dry ap‐ pearance, dry sensation, and stinging sensation.[8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
